



**ADVITECH APPOINTS MS. CHRISTINA JUNEAU
AS VICE-PRESIDENT RESEARCH AND DEVELOPMENT**

TSX VENTURE EXCHANGE: AVI

FOR IMMEDIATE RELEASE

QUÉBEC – December 16, 2005 - Renaud Beaudesne, President and Chief Executive Officer of Advitech (TSX-V: AVI), today announced the appointment of Christina Juneau, Ph.D., as Vice-President, Research and Development. The appointment took effect December 14, 2005. Dr. Juneau was previously Director, Scientific Affairs for Advitech and was in charge of the recent clinical study on Dermylex™, Advitech's product for psoriasis. She has also led other critical projects during the past months, including the recent successful study on inflammatory bowel diseases.

Christina Juneau has a Ph.D. in Food Science and a B.Sc. in Biochemistry, both from Université Laval. She has over 12 years of experience in the biotech industry. She co-founded a leading Canadian biotech company at which she was involved in several scientific and regulatory aspects of product development, manufacturing and marketing. She is co-author of more than ten patents and two patents pending related to the development, manufacturing and use of bio-active compounds destined for use in various medical applications.

"Christina played a major role in the progress we have accomplished this year in our R&D program. She is a team player and provides our team with vast experience. This will be important as we move toward commercialization of our products," Renaud Beaudesne stressed.

About Dermylex™

Dermylex™ is Advitech's orally administered product for mild to moderate psoriasis with proven clinical efficacy. On July 5, 2005, the Company reported positive results from its Phase II clinical trial for mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of Dermylex™ for treating mild to moderate psoriasis.

About Advitech

Advitech is a Canadian biotechnology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (I.M.I.D.), such as psoriasis and inflammatory bowel diseases. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

-30-

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.

Michel Lamontagne, MBA
Vice-President and Chief Financial Officer
(418) 686-7498, ext. 237
m.lamontagne@advitech.com
www.advitech.com

For Investors

Echoes Financial Network Inc.

Dominic Sicotte, (514) 842-9551, ext. 236
Martin Lavoie, (514) 842-9551, ext. 231
www.roadshows.tv